2022
Adherence to Guidelines in Heart Failure, Is It Valid for Elderly Patients?
Khoury J, Ghersin I, Braun E, Elias A, Aronson D, Azzam Z, Bahouth F. Adherence to Guidelines in Heart Failure, Is It Valid for Elderly Patients? Israel Medical Association Journal 2022, 24: 757-762. PMID: 36436045.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureAngiotensin receptor blockersPatients 80 yearsEjection fractionHeart failureMedicine groupSingle-center retrospective studyDecompensated heart failureReduced ejection fractionLarge prospective studiesRandomized clinical trialsOlder adult populationGDMT groupMineralocorticoid antagonistsCause mortalityReceptor blockersValue of guidelinesElderly patientsHospital dischargeOlder patientsYounger patientsMedical therapyPrimary outcomeProspective studyRetrospective studyImmunity waning after COVID vaccine booster vs. infection—better than expected
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Immunity waning after COVID vaccine booster vs. infection—better than expected. Infectious Diseases 2022, 54: 828-831. PMID: 35796285, DOI: 10.1080/23744235.2022.2097304.Peer-Reviewed Original ResearchConceptsBooster doseSecond doseThird doseSecond boosterBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 PCRIgG antibody titresBAU/mLCOVID-19 vaccineEMMS Nazareth HospitalVaccine boosterSuggestive symptomsMean titresNasopharyngeal swabsProspective studyAsymptomatic infectionDoses groupsAntibody titresBooster groupGeneral populationHigh titresDoseTitresDoses
2021
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine – Long term immune decline and breakthrough infections. Vaccine 2021, 39: 6984-6989. PMID: 34763949, PMCID: PMC8556595, DOI: 10.1016/j.vaccine.2021.10.038.Peer-Reviewed Original ResearchConceptsAntibody titersCOVID-19 vaccineBreakthrough infectionsSecond doseAntibody levelsPolymerase chain reactionBNT162b2 mRNA COVID-19 vaccineSARS-CoV-2 polymerase chain reactionMRNA COVID-19 vaccineStudy periodBreakthrough infection rateMedian antibody levelsMean antibody levelsLongitudinal prospective studyAntibody declineTiter elevationImmune declineProspective studyClinical indicationsMild casesHealthcare personnelInfection rateInfectionVaccinePeak levels